Saving Seafood

Major Chinese fish oil producer and exporter Shandong Yuwang Pharmaceutical approved Friend of the Sea

November 19, 2018 — The following was released by Friend of the Sea:

Chinese manufacturer Shandong Yuwang Pharmaceutical Co. Ltd. has obtained Friend of the Sea certification for refined fish oil and softgel from Engraulis rigens sourced from FAO Area 87 (Southeast Pacific).

Friend of the Sea’s standard for sustainable fish oil and Omega-3 certifies that the oil originates only from fisheries that are compliant with Friend of the Sea’s sustainable fishing requirements, including good fishery management, selective fishing gears and social responsibility, and that a full chain of custody is in place throughout the supply and production chain.

Shandong Yuwang Pharmaceutical Co. Ldt., which processes 20000 tons of crude fish oil and produces 10000 tons of refined fish oil, is one of the largest world’s manufacturer of refined fish oil. While being exported to America and Europe, the finished fish oil also guarantees material supply of stringent standard’s fish oil preparation and products for Yuwang itself.

“We decided to join the Friend of the Sea project because we are eager to give our contribution in conserving the marine habitats and protecting them for future generations,” claims Albert Ho, Business Manager at Shandong Yuwang Pharmaceutical.

“The approval of Shandong Yuwang Pharmaceutical as a Friend of the Sea certified company consolidates the presence of our certification in China and is the confirmation that more and more fish oil manufacturers are committed towards environmental sustainability” comments Paolo Bray, Founder and Director of Friend of the Sea.

Recent studies say fish oil could boost your heart

November 16, 2018 — Heart disease is the leading killer in America, and San Antonio is no exception.

But as the Washington Post reports, two recent major studies point to the possibility that medications derived from fish oils could help protect people from heart attacks, strokes and other types of cardiovascular ailments. These are medications, not supplements.

The long-term studies involved two drugs derived from omega-3 fatty acids. Both studies found the drugs, if taken appropriately, made a significant difference for people with diabetes or heart disease.

Read the full story at the San Antonio Express

Should You Keep Taking Those Fish Oil And Vitamin D Pills?

November 16, 2018 — Nearly 19 million Americans take fish oil supplements and some 37 percent of us take vitamin D. Many may be motivated by research that has suggested these pills can protect heart health and prevent cancer. On Saturday, NPR published a story on long-awaited research on both supplements that called those claims into question.

The findings of the trial, called VITAL, were complex. When researchers looked at cancer and overall cardiovascular events, they found no protective benefit from taking vitamin D or fish oil supplements. But when they looked only at heart attacks, they did find a benefit, especially for African-Americans and people who eat little fish. (Researchers say further study is needed to see whether those benefits hold up.)

The story prompted a wave of questions from our readers and listeners. Many of you wrote in asking, essentially, should I stop taking these supplements?

To get answers to some of your questions, we spoke with Dr. JoAnn Manson, chief of the Division of Preventive Medicine, Department of Medicine, at Brigham and Women’s Hospital, who headed the VITAL trial. We also turned to Dr. Bess Dawson-Hughes, senior scientist and director of the Bone Metabolism Laboratory at Tufts University School of Medicine.

The findings of the VITAL study cast doubt on benefits of fish oil for cancer and cardiovascular disease. Should people just throw out their pills?

JoAnn Manson: No. For those already taking supplements, our findings do not offer a clear reason to stop. If you want to consider starting, our recommendation is to talk with your health care provider, but this does not need to be done on an urgent basis. We do caution against taking very high doses, but at the level fish oil [was taken] in our study there were no significant adverse effects. In addition, while fish oil did not reduce the risk of stroke or other cardiovascular problems, it did reduce the risk of heart attack by 28 percent and that is a significant finding.

Previous research suggests fish oil may have greater benefits for heart health than for reducing stroke, because there are some mechanisms — such as reducing irregular heart rhythm — which would be more important for heart attack than for stroke.

Read the full story at NPR

Fish-oil drugs protect heart health, two studies say

November 12, 2018 — Two major studies released Saturday provide evidence that medications derived from fish oil are effective in protecting people from fatal heart attacks, strokes and other forms of cardiovascular disease.

The large, multiyear research efforts tested different formulations and quantities of drugs made with Omega-3 fatty acids on two groups of people: one that suffered from cardiovascular disease or diabetes and another that represented the general population. Both studies found that people who took the drugs every day enjoyed protection against some heart and circulatory problems compared with those given a placebo.

In a look at another commonly consumed supplement, vitamin D, researchers found no effect on heart disease but saw a link to a decline in cancer deaths over time.

The research was released Saturday at the American Heart Association’s 2018 Scientific Sessions in Chicago and published in the New England Journal of Medicine.

About 43 million people in the United States take statins to lower LDL, or “bad,” cholesterol, and the drugs are credited with reducing the risk of heart attacks and strokes. But heart disease remains the leading killer of Americans. In recent years, a long, steady decrease in heart disease deaths has slowed. So researchers are seeking other ways to combat cardiovascular disease beyond known protective factors such as changes in diet, exercise and smoking habits.

One of the studies unveiled Saturday, named by the acronym REDUCE-IT, determined that people with cardiovascular disease who were already taking statins stood less chance of serious heart issues when they were also given two grams of the drug Vascepa (icosapent ethyl) twice a day.

Read the full story at The Washington Post

Decades-long study ties omega-3s from seafood to healthier aging

October 25, 2018 — A study of over 2,500 adults between 1992 and 2015 has found that omega-3 polyunsaturated fatty acids present in seafood reduce the risk of unhealthy aging.

The study, published in BMJ, started with adults at an average age of 74 in 1992 and examined the levels of four different omega-3s – eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and alpha linolenic acid (ALA) – present in their body. Over the course of the study, participants were surveyed regularly, and in three periods – 1992-1993, 1998-1999, and 2005-2006 – had the omega-3s present in their blood measured.

The study found, after correcting for other factors such as age, sex, and race, that adults with higher levels of EPA and DPA had a better chance of healthy aging. Participants with the highest level of omega-3s present had an 18 percent lower risk of unhealthy aging. Participants with the highest levels of EPA and DPA, the omega-3s commonly found in seafood, had the best results: Those with high levels of EPA had a 24 percent lower risk of unhealthy aging, and those with DPA had an 18 percent lower risk of unhealthy aging.

“We found that older adults who had higher levels of omega 3 from seafood were more likely to live longer and healthier lives,” lead study author Heidi Lai of the Friedman School of Nutrition Science and Policy at Tufts University in Boston told Reuters. “These findings support current national dietary guidelines to consume more seafood.”

The study also found that levels of DHA from seafood and ALA from plants did not seem to have an impact on whether the participant would age healthily or not.

“Docosahexaenoic acid from seafood and alpha-linolenic acid from plants were not associated with a lower likelihood of unhealthy ageing,” states the report.

Read the full story at Seafood Source

Omega-3s in Fish Oils Tied to Healthy Aging

October 19, 2018 — Higher blood levels of omega-3 fatty acids, the fats found in fish, are linked to a healthier old age, according to a new study.

Researchers tracked 2,622 adults, average age 74 and healthy at the start of the study, from 1992 to 2015, looking to see if they continued to live without chronic diseases and without mental or physical problems.

The investigators measured blood levels of four common types of omega-3s: EPA and DHA, found in seafood; ALA, derived from plants; and DPA, which the body produces in small amounts.

After adjusting for many medical, dietary and lifestyle factors, they found that compared with people in the lowest one-fifth for omega-3 levels, those in the highest one-fifth had an 18 percent lower risk of unhealthy aging. The study appeared in BMJ.

Considered separately, EPA and DPA were associated with lowered risk of unhealthy aging, but DHA and ALA were not.

Read the full story at The New York Times

Fishmeal industry optimistic on upcoming Peruvian anchovy season

October 15, 2018 — Fishmeal and fish oil industry sources are optimistic about the upcoming Peruvian anchovy fishing season, which might start earlier than expected, in mid-November.

Peru’s ministry of production (Produce) is expected to announce the start of the fishing season around the end of October, taking into account the outcome of the maritime institute’s ongoing evaluation.

“Sea conditions are optimal and good reproduction has already started on the acoustic cruise that will end at the end of October,” said Humberto Speziani, IFFO board member and former president of IFFO and of the Peruvian National Fisheries Society (SNP).

Although the evaluation hasn’t yet been completed, it seems that biomass in the water is abundant, which could lead to a quota of 2 million-2.5m metric tons, according to sources. Despite rumors that the quota could be as high as 2.5m metric tons, 2m-2.2m metric tons is more in line with the historical average, one source pointed out.

“2m-2.5m metric tons is quite a reliable assumption of quota,” Jean-Francois Mittaine, an analyst with 30 years experience in the sector, told Undercurrent News, adding that fishmeal and fish oil prices were currently “quite stable”.

Super prime fishmeal is currently priced at around $1,630-1,650 per metric ton, while fish oil is at around $1,350/t, according to industry sources in Peru. Meanwhile, prices in China were slightly falling, driven by expectations of a good upcoming Peruvian season, according to sources.

Read the full story at Undercurrent News

SFP: Reduction fishery sustainability improving, Asian fisheries still an issue

October 9, 2018 — The Sustainable Fisheries Partnership has released its latest annual report on reduction fisheries, and has concluded that the sustainability of the fisheries worldwide has improved by roughly eight percent.

The report, which analyzed 26 reduction fisheries – fisheries that harvest fish to be processed into fishmeal and fish oil – found that the amount of catch coming from poorly managed fisheries has dropped 16 percent from last year, and has been steadily decreasing since 2016. The report also found the 91 percent of the catch volume came from stocks “that scored 6 or better on all five criteria outlined by SFP’s FishSource database,” according to SFP.

While the report is positive, the authors – Pedro Veiga, Marina Mendes, and Blake Lee-Hardwood – also noted that Asian fisheries have been largely excluded from the data, “because of the current difficulty in establishing management and catch data.”

“This omission is significant, because the fisheries of Asia provide very large quantities of fishmeal; it is hoped that future editions of the report will be able to extend coverage to at least some of these fisheries,” the authors wrote. “Nonetheless, we are confident that the report covers approximately 50 percent of global fishmeal and oil production.”

Roughly three percent of the total catch volume of what was included in the report is coming from fisheries that have stock in “very good condition.” The entirety of that amount is attributed to one fishery: Antarctic krill in the Atlantic Southern Ocean. Of the 91 percent of fisheries that are “reasonably well-managed” or better, the largest contributor was the Peruvian anchoveta fishery, representing 33 percent of the total catch.

“This report clearly identifies a positive trend among the reduction fisheries of the North Atlantic and Eastern Pacific, although there is still significant room for improvement with some fisheries,” the authors wrote. “The proportion of fisheries achieving higher sustainability ratings has increased significantly; this builds on improvements identified in the previous report for 2017. These results clearly represent a good news story for the fishmeal and fish oil industry and show that it is becoming ever more responsible with regards to fisheries management.”

Industry leaders within aquaculture were pleased by the news in the report.

“BioMar is proud to support SFP in its efforts to improve the environmental stewardship of global marine resources. The positive trend in this year’s report demonstrates the power of the multi-stakeholder approach to “greening” value chains through responsible sourcing,” BioMar sustainability specialist Erik Olav Gracey said. “We will continue to actively support SFP through collaboration and support of fisheries improvement projects worldwide.”

Read the full story at Seafood Source

SFP sees improvement in sustainability of fisheries used for fishmeal, oil

October 9, 2018 — More than 90% of the fish used for fishmeal and fish oil from the Atlantic and eastern Pacific oceans now come from fisheries that are “reasonably well-managed (or better)”, according to the latest annual report on reduction fisheries by the Sustainable Fisheries Partnership (SFP).

SFP said its report, which analyzes 26 reduction fishery stocks worldwide, found that 91% of the total catch volume came from stocks that scored 6 or better on all five criteria outlined by SFP’s FishSource database. That’s an 8% increase over last year.

Poorly managed fisheries accounted for 9% of the catch, a drop from 16% last year.

Of the stocks listed in “very good condition,” the report singled out the Antarctic krill fishery in the Atlantic Southern Ocean as being particularly well-managed by the Commission for the Conservation of Antarctic Marine Living Resources.

Read the full story at Undercurrent News

Fish Oil Drug May Reduce Heart Attack and Stroke Risks for Some

September 26, 2018 — Cardiologists may one day have a new tool to help prevent heart attacks and strokes in some high-risk patients: a prescription drug that contains large doses of EPA, an omega-3 fatty acid contained in fish oil.

A large clinical trial found that the drug, called Vascepa, sharply reduced the rate of cardiovascular events in people with a history of heart disease or Type 2 diabetes, according to early results that were announced on Monday.

The findings were particularly relevant for people with high triglycerides, a type of fat in the blood that has been linked to an increased risk of heart disease. The new trial, called Reduce-IT, focused on people whose cholesterol levels were well controlled with statins but whose triglyceride levels remained very high. Many cardiovascular experts were doubtful that adding fish oil on top of statins would produce much if any benefit because a number of smaller and less rigorous studies over the years had failed.

But the new trial showed that statin-treated adults with elevated triglycerides who were prescribed high doses of the purified EPA had a 25 percent reduction in their relative risk of heart attacks, strokes and other cardiac events compared to a control group of patients who received placebo.

Read the full story at The New York Times